Low testosterone doesn’t announce itself with a diagnosis. It arrives quietly as fatigue you explain away, motivation you can’t quite find, and a distance in your relationship you don’t know how to name.
Testosterone pellet therapy at MENZ Clinic restores what time has taken. One brief procedure. Steady hormone levels for 3–5 months. No weekly injections. No daily gels. Physician-supervised and lab-guided from day one.
Men who come to MENZ Clinic typically haven’t been sleeping well, haven’t felt like themselves in the gym, and have noticed something changing in their relationship but they haven’t talked to anyone about it. There’s a particular kind of quiet frustration that comes with declining testosterone, because the symptoms arrive gradually enough that men convince themselves it’s just stress, or age, or not getting enough sleep. By the time they’re in my office, some of them have been managing these symptoms for years.
I’ve been practicing medicine for over 25 years. The men I see are not looking for a shortcut they want to understand what’s happening in their body and do something real about it. Testosterone pellet therapy fits that need precisely. It’s a medically rigorous, lab-guided protocol. We measure your levels before we treat you. We dose based on your labs, your weight, your symptom burden. We follow up. When we get it right, what men describe isn’t just ‘feeling better’, it’s feeling like themselves again.
That’s what I’m here for. Not a 15-minute telehealth form and a shipment in the mail. A physician who knows your name and your numbers.
Men rarely lead with ‘I think my testosterone is low.’ They come in describing a combination of symptoms that have been dismissed or explained away for months, sometimes years. The fatigue that doesn’t resolve with sleep. The body composition shift that persists despite exercise. The erosion of drive, competitive edge, and sexual confidence that men find difficult to articulate, let alone discuss.
The relationship impact is real and often goes unspoken. Reduced libido affects partners as well as patients. Erectile changes that emerge from hormonal imbalance and testosterone deficiency contributes meaningfully to ED affect intimacy, communication, and self-confidence in ways that extend well beyond the bedroom. These are not trivial quality-of-life issues. They are the issues that matter most to men in the prime decades of their lives.
At MENZ Clinic, this conversation is normal. There is no judgment her only clinical precision and a physician who has had this conversation with thousands of men across Central Florida over 25 years of practice.
• Persistent fatigue unrelieved by sleep
• Reduced sex drive noticeably lower than baseline
• Erectile changes difficulty achieving or maintaining erection
• Loss of muscle mass despite regular training
• Increase in abdominal fat, especially visceral
• Brain fog, reduced focus, difficulty with word recall
• Irritability, low mood, reduced sense of drive or ambition
• Poor sleep quality difficulty staying asleep, non-restorative sleep
• Reduced competitiveness, motivation, and self-confidence
• Longer recovery from exercise, reduced training capacity
Testosterone pellets are small, custom-dosed cylinders roughly the size of a grain of rice made of compressed, pharmaceutical-grade testosterone. They are inserted beneath the skin in a brief, in-office procedure that typically takes 10–15 minutes under local anesthesia. The most common insertion site is the upper gluteal region, just below the hip. Most men describe the procedure as minimal discomfort significantly less intimidating than the description suggests.
Once placed, the pellets dissolve gradually over 3–5 months, releasing testosterone directly into the bloodstream in a consistent, physiologically steady manner. This is the critical distinction from other delivery methods: there are no peaks of supraphysiological hormone followed by valleys of deficiency, as commonly seen with weekly injections. No daily reminder to apply a gel or worry about transference to a partner or child. The hormone is present consistently, in the background, without requiring anything of you day to day.
Dosing at MENZ Clinic is individualized to your lab results. Total testosterone, free testosterone, SHBG, estradiol, PSA, CBC, and a comprehensive metabolic panel are all evaluated before any prescription is written. The number and dose of pellets is calculated based on your specific deficiency, your body weight, your symptom burden, and your clinical presentation not a one-size-fits-all protocol.
Duration: 10–15 minutes in-office under local anesthesia
Insertion site: Upper gluteal region (flank/upper hip area)
Pellet size: Approximately 3mm × 9mm smaller than a Tic Tac
Duration of effect: 3–5 months (individual variation based on metabolism and activity level)
Downtime: None avoid immersion (pools, hot tubs) and strenuous lower body exercise for 3–5 days
First follow-up labs: 4–6 weeks post-insertion to confirm optimal serum levels
Ongoing monitoring: Labs and clinical reassessment every insertion cycle
of Men Over 70 Have Clinically Low Testosterone
Harman et al. age-related testosterone decline begins in the 3rd decade; 1–3% loss per year
Point Improvement in IIEF Erectile Function Score with Testosterone Therapy vs. Placebo
Corona et al., Eur Urol 2017 | PMID 28434676 | Meta-analysis of 14 RCTs, N=2,298
Sustained Testosterone Release from a Single Pellet Insertion
McCullough et al., Curr Sex Health Rep 2014 PMC4431706; testosterone levels remain therapeutic for duration before requiring re-insertion
Men in the TRAVERSE Sexual Function Study TRT Improved Sexual Activity and Libido Scores vs. Placebo
Basaria et al. / TRAVERSE nested study | PMID 37589949 | NEJM 2024 | Men 45–80, T <300 ng/dL
European Urology, 2017. Meta-analysis of 14 randomized placebo-controlled trials enrolling 2,298 hypogonadal men (mean age 60.2 years, mean follow-up 40.1 weeks). Testosterone therapy (TTh) significantly improved erectile function (mean IIEF-EFD improvement 2.31 points; p<0.0001) compared to placebo. Effect was greatest in men with more severe hypogonadism (T<8 nmol/L). Libido, intercourse satisfaction, orgasm quality, and overall sexual satisfaction all improved significantly. Conclusion: sexual dysfunction should be recognized as a hallmark manifestation of testosterone deficiency. PMID: 28434676
Nested within the landmark TRAVERSE cardiovascular outcomes trial (N=5,204 men, 45–80 years, T<300 ng/dL). The Sexual Function substudy enrolled 1,161 men with low libido (587 TRT, 574 placebo). Primary outcome: change in sexual activity score. Results: TRT significantly improved sexual activity and hypogonadal symptom scores and significantly increased sexual desire over 2 years. Erectile function improvement was statistically non-significant in this subset reflecting the known nuance that TRT is most effective for ED in men with more severe testosterone deficiency. NOTE: Evidence is strongest for libido and sexual activity outcomes; severe vasculogenic ED may require additional treatment (P-Shot, GAINSWave, PDE5 inhibitors). PMID: 37589949
Current Sexual Health Reports, 2014. Comprehensive pharmacokinetic and clinical review of subcutaneous testosterone pellet therapy (Testopel and compounded formulations). Key findings: pellets maintain testosterone levels above 315 ng/dL for 12+ weeks post-insertion; peak levels at approximately 3 weeks; erectile function scores (IIEF) increased clinically significantly in the first 12 weeks of treatment; both pellet and injection groups reported consistent subjective improvement in libido, potency, muscular strength, and general well-being. Limitation: the study noted biologic variability in treatment effect from one insertion cycle to the next. PMID: PMC4431706
Journal of Sexual Medicine, 2014. Largest meta-analysis of testosterone supplementation and sexual function, including 41 randomized controlled trials. Testosterone supplementation significantly improved erectile function and other sexual response parameters in hypogonadal men. Authors noted that evidence is stronger and more consistent in clearly hypogonadal subjects (total T <300 ng/dL); the benefit in eugonadal men is uncertain. Synergism with PDE5 inhibitors was identified: TTh can rescue PDE5i non-responders who are subsequently found to be hypogonadal. PMID: 24697970
Randomized, open-label, single-center trial comparing a compounded testosterone pellet (E100, 750mg) with FDA-approved Testopel (700mg) in men with testosterone deficiency (T<300 ng/dL). Both formulations produced equivalent non-inferior testosterone levels and equivalent symptom improvement across energy, libido, mood, and erectile function measures. Safety profiles were comparable. Key clinical implication: physician-supervised compounded pellets administered by trained providers using individualized dosing produce outcomes comparable to the branded formulation. NOTE: Strict exclusion criteria limit external validity; real-world clinical outcomes may vary with dosing precision. PMID: PMC10022718
Testosterone therapy is most clearly beneficial for men with confirmed hypogonadism (total T ≤300 ng/dL with symptoms). Its benefits in men with low-normal or borderline testosterone levels are uncertain and inconsistent across trials. Erectile dysfunction: TRT is effective for ED in hypogonadal men particularly mild to moderate ED driven primarily by hormonal deficiency. For men with more severe or vasculogenic ED (ED driven by blood flow issues rather than hormonal deficiency), TRT alone may be insufficient and is best combined with GAINSWave, P-Shot, or PDE5 inhibitors as clinically appropriate. Mood and energy: The TRAVERSE trial and other RCTs found inconsistent or non-significant effects of TRT on mood and energy scores. The clinical impression of improved energy and mood is common in patients but controlled trial data are weaker here than for sexual function outcomes. Fertility: Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and significantly reduces sperm production. Men who wish to preserve fertility should discuss alternative approaches (Clomid/enclomiphene) before beginning any form of TRT. Cardiovascular safety: The TRAVERSE trial (N=5,204; PMID 37589949) found no significant increase in MACE (major adverse cardiovascular events) with TRT in men at elevated cardiovascular risk an important safety reassurance. However, TRT is associated with a significantly elevated risk of erythrocytosis (elevated red blood cell count), which requires monitoring with CBC at each follow-up visit.
Note: Dr. J offers all three delivery methods at MENZ Clinic. The best option is determined at consultation based on your labs, lifestyle, and clinical presentation not a default protocol.
Frequency: Every 3–5 months
Hormone Consistency: Steady, physiologic
Home Use Required: None
Partner Transfer Risk: None
Dosing Flexibility: Per insertion cycle
In-Office Procedure: Yes (minor, 10–15 min)
Best For: Men who want consistency without daily/weekly maintenance
Frequency: Weekly or bi-weekly
Hormone Consistency: Peaks & valleys
Home Use Required: Self-injection at home
Partner Transfer Risk: None
Dosing Flexibility: Adjustable weekly
In-Office Procedure: No
Best For: Men wanting frequent dose adjustability
Frequency: Daily
Hormone Consistency: Daily self-application
Home Use Required: Self-injection at home
Partner Transfer Risk: Yes skin contact risk
Dosing Flexibility: Adjustable daily
In-Office Procedure: No
Best For: Men averse to procedures or injections
Individual results depend on baseline testosterone levels, dosing precision, and the degree to which testosterone deficiency was driving a given patient’s symptoms. Men with clearly confirmed hypogonadism total testosterone below 300 ng/dL with consistent symptoms experience the most predictable and meaningful response.
Known or suspected prostate cancer. TRT is contraindicated in men with active or high-risk prostate cancer. Breast cancer in men. Polycythemia or untreated erythrocytosis (hematocrit >54%). Active desire to father children. TRT suppresses sperm production; discuss fertility preservation options first. Severe untreated sleep apnea. Hypersensitivity to testosterone or pellet components
Elevated PSA requires further urology evaluation before beginning TRT. Hematocrit approaching 50% CBC monitoring essential; dose adjustment may be required. Severe lower urinary tract symptoms (LUTS) / BPH TRT can worsen urinary obstruction in some men. History of deep vein thrombosis or pulmonary embolism elevated erythrocytosis risk requires careful monitoring. Concurrent use of anticoagulants discuss at consultation. BMI >35 pellet dissolution rate may be altered by higher metabolic demand; dose may need adjustment
1) Lab Panel (Required Before Consultation): Dr. J requires comprehensive labs before any treatment discussion or prescription. Labs include: total and free testosterone (morning draw), SHBG, estradiol, PSA, CBC with differential (hematocrit), comprehensive metabolic panel, thyroid function, lipid panel, and LH/FSH to characterize the type of hypogonadism. Same-day or next-day labs available through our Sand Lake facility. Results are reviewed by Dr. J before your consultation.
2) Physician Consultation with Dr. J: Dr. J reviews your lab results in the context of your complete medical history, current medications, symptom duration and severity, relationship and sexual health history, and personal goals. This is a physician consultation not a nurse assessment. Dr. J discusses all available treatment options (pellets, injections, gels), the evidence base for each, and the clinical rationale for his recommendation. You leave informed, not just prescribed.
3) Pellet Insertion Procedure (If Appropriate): If testosterone pellet therapy is the agreed plan, the procedure can typically be performed at the same visit. The upper gluteal area is cleansed and numbed with local anesthetic. A small incision is made and the pellets dosed specifically to your labs and weight are inserted subcutaneously. The incision is closed with a single Steri-Strip. Total procedure time: 10–15 minutes. You leave the office able to drive and return to most normal activities.
4) Post-Procedure Instructions: Avoid immersion in pools, hot tubs, or lakes for 3–5 days. Avoid strenuous lower body exercise (squats, running, cycling) for 3–5 days to allow the insertion site to heal. Showering is fine after 24 hours. The pellets are not palpable in most patients after the first week. Contact us immediately if you notice signs of infection (redness, warmth, drainage) at the insertion site rare but addressed promptly.
5) Follow-Up Labs at 4–6 Weeks: A follow-up lab draw at 4–6 weeks confirms that serum testosterone levels are in the target range (typically 600–900 ng/dL, individualized to your baseline and symptom response). Hematocrit is checked to monitor for erythrocytosis. If levels are suboptimal, a dosing adjustment is made at the next insertion. Most patients hit the target range reliably by the second insertion cycle once the dose is calibrated.
6) Re-Insertion at 3–5 Months: When hormone levels begin to decline typically at 3–5 months depending on individual metabolism and activity level patients return for their next insertion cycle. Labs are drawn again, dose is reviewed and adjusted if needed, and the cycle begins again. Most men settle into a reliable 3–4 month re-insertion rhythm. Over time, many patients and Dr. J develop an accurate sense of when levels are beginning to drop based on symptom pattern.
Most men notice improved energy and sense of well-being within the first 2–3 weeks. Libido improvements often become apparent at 3–4 weeks. The full effect on body composition, strength, and sexual performance typically develops over the first 2–3 months as testosterone levels stabilize in the therapeutic range. Individual response varies based on how deficient you were at baseline and how long you’ve been symptomatic.
Yes, all forms of exogenous testosterone suppress the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH signals to the testes and decreasing sperm production significantly. Men who wish to father children in the future should discuss this with Dr. J before beginning treatment. Alternative options Clomid (clomiphene citrate), enclomiphene, or hCG can help maintain fertility while supporting testosterone levels in appropriate candidates.
TRT is contraindicated in men with active or suspected prostate cancer. For men without prostate cancer, TRT generally produces a modest, predictable rise in PSA (typically 0.3–0.5 ng/mL) that stabilizes within the first few months. Dr. J monitors PSA at each follow-up. The current evidence does not support a causal relationship between TRT and prostate cancer development in men with normal baseline PSA but monitoring is essential and any significant PSA increase warrants urology evaluation.
Online TRT services typically operate via asynchronous telehealth intake forms, reviewed by non-physician providers, with medication shipped to your door. What they don’t provide: comprehensive physician evaluation, in-person clinical assessment, detection of contributing factors (thyroid, metabolic contributors), or ongoing dose optimization by a physician who knows your clinical history. Dr. J is your physician not a rotating pool of providers. He reads your labs, makes your recommendations, and performs your procedure personally. That distinction matters when the treatment involves hormones.
Yes, and for many men, combination is the right clinical approach. Testosterone optimizes the hormonal environment; GAINSWave acoustic wave therapy addresses vascular ED by promoting blood vessel regeneration; P-Shot PRP enhances tissue responsiveness. Men with both hormonal and vascular contributors to ED frequently benefit from combining these approaches. Dr. J discusses the clinical case for each at consultation based on your complete picture.
Cost is determined by the number and dose of pellets required, which varies by patient based on lab-guided dosing. MENZ Clinic does not accept insurance for this service testosterone pellet therapy is a cash-pay treatment. Financing options are available. Exact pricing is provided at consultation after labs are reviewed and dosing is determined. Pricing is transparent no surprise fees.
The 300 ng/dL threshold is a clinical guideline, not a biological absolute. Men with levels in the 300–400 ng/dL range with significant symptoms particularly men who are older, have higher SHBG (which reduces free testosterone), or have significant symptom burden may still be appropriate candidates for a therapeutic trial. Dr. J evaluates free testosterone and SHBG alongside total testosterone, and makes candidacy decisions based on the complete clinical picture, not the total testosterone number alone.
The first step is simple: a conversation and your labs. Dr. J does not prescribe testosterone pellets without reviewing your lab results and you should not accept a prescription from any provider who does. The consultation is your opportunity to understand what your numbers mean, what options exist, and whether testosterone pellet therapy is the right choice for your clinical picture.
Men in Central Florida have been trusting Dr. J with their most sensitive health concerns for over 25 years. More than 1,000 five-star reviews across the practice reflect what that trust looks like in practice. We are not a volume clinic. We are a physician-led practice that takes men’s health seriously.
